Premium
Donor Leukocyte Transfusions for Treatment of Leukemic Relapse after Bone Marrow Transplantation
Author(s) -
Kolb HJ.
Publication year - 1998
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.1998.tb05438.x
Subject(s) - medicine , chronic myelogenous leukemia , leukemia , myeloid leukemia , bone marrow , multiple myeloma , immunology , transplantation , myelodysplastic syndromes , bone marrow transplantation , myeloid
Allogeneic bone marrow transplantation is an effective treatment of leukemia. Intensive chemo‐ and radiotherapy used for conditioning and T‐cells of the graft contribute to the control of leukemia. Animal experiments indicate that transfusion of lymphocytes from the marrow donor convert into complete chimerism without producing graft‐versus‐host disease, if delayed for two months or more. Transfusion of donor leukocytes (DLT) after marrow transplantation has induced lasting remissions in the majority of patients with chronic myelogenous leukemia (CML) in hematological or cytogenetic relapse, some patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), transformed phase CML and multiple myeloma (MMY). The mechanism of the graft‐versus‐leukemia reaction is discussed.